Last reviewed · How we verify

Paclitaxel + Trastuzumab — Competitive Intelligence Brief

Paclitaxel + Trastuzumab (Paclitaxel + Trastuzumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane + monoclonal antibody. Area: Oncology.

phase 3 Taxane + monoclonal antibody Microtubules + HER2/neu receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Paclitaxel + Trastuzumab (Paclitaxel + Trastuzumab) — Institut de cancérologie Strasbourg Europe. Paclitaxel works by inhibiting microtubule dynamics, thereby inducing cell cycle arrest and apoptosis in rapidly dividing cancer cells. Trastuzumab targets the HER2/neu receptor, which is overexpressed in certain breast cancer cells, and triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Paclitaxel + Trastuzumab TARGET Paclitaxel + Trastuzumab Institut de cancérologie Strasbourg Europe phase 3 Taxane + monoclonal antibody Microtubules + HER2/neu receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane + monoclonal antibody class)

  1. Institut de cancérologie Strasbourg Europe · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paclitaxel + Trastuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-trastuzumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: